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Survivin, a new member of the family of apoptosis inhibitors, is expressed almost exclusively in proliferating cells, above all in cancers.
Subcellular localisation and prognostic implications of the survivin protein have not yet been determined in oesophageal squamous
cell carcinoma. The survival of 84 patients with oesophageal squamous cell carcinomas was correlated with the extent of
immunohistochemical survivin expression in tumour cell nuclei. Tumours were scored positive when 45% cells stained positive.
Patients were followed up for at least 5 years or until death. In normal oesophageal squamous cell epithelium, some cytoplasmic
survivin expression was detected in the basal cells, whereas proliferating cells showed nuclear staining of survivin. Nuclear expression
of survivin was also detected in 67 cancers (80%). The mean survival for patients of this group (28 months, range 20–36) was
significantly less than that for patients without survivin expression in the tumour cell nuclei (108 months, range 62–154, P¼0.003).
Using univariate analysis, nuclear survivin expression (P¼0.003), tumour depth (P¼0.001), lymph node metastasis (P¼0.003) and
stage (Po0.001) were the best predictors of survival. In contrast, cytoplasmic survivin staining was noted in 53 (63%) tumours and
had no prognostic relevance. In conclusion, the analysis of nuclear survivin expression identifies subgroups in oesophageal squamous
cell cancer with favourable (survivin
 ) or with poor prognosis (survivin
+). We suggest that the determination of nuclear survivin
expression could be used to individualise therapeutic strategies in oesophageal squamous cell cancer in the future.
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Apoptosis plays an important role in organ homeostasis,
eliminating senescent or damaged cells (Vaux and Korsmeyer,
1999). Impairment of apoptosis facilitates the accumulation
of gene mutations by prolonging the cell cycle span and
promoting resistance to immune-based cytotoxicity (Yang and
Korsmeyer, 1996), finally contributing to carcinogenesis
(Thompson, 1995).
It has been shown recently that the inhibitor of apoptosis
proteins (IAP) are crucial regulators of the molecular mechanisms
of apoptosis (Deveraux and Reed, 1999). Among the IAP members,
survivin is unique in that it was found to be expressed in foetal
tissue and in a variety of human cancers, but not in nonproliferat-
ing adult tissues (Ambrosini et al, 1997). Survivin inhibits
apoptosis in cells exposed to diverse apoptotic stimuli by
associating with microtubules of the mitotic spindles (Li et al,
1998) and inhibiting caspase-3 and caspase-7 activity (Tamm et al,
1998). Overexpression of survivin has oncogenic potential because
it may overcome the G2/M phase checkpoint to enforce progres-
sion of cells through mitosis. However, the biological functions of
survivin, other than its apoptotic effect, are not well understood in
human cancer. Expression of survivin protein is highly correlated
with more aggressive forms of neuroblastoma (Adida et al, 1998)
and oral and skin squamous cell carcinoma (Lo Muzio et al, 2001),
and poor survival in patients with neuroblastoma (Adida et al,
1998), colorectal cancer (Kawasaki et al, 1998), nonsmall-cell lung
cancer (Monzo et al, 1999), breast cancer (Tanaka et al, 2000) and
increasing rates of recurrence in bladder cancer (Sherr and
Roberts, 1995). By investigating mRNA expression of survivin,
Kato et al (2001) found a significant correlation with a poorer
prognosis and a worse response to chemotherapy in oesophageal
cancer. Nevertheless, the expression and function of the survivin
protein in oesophageal squamous cell carcinoma (SCC) is yet to be
determined.
Therefore, we investigated the protein expression of survivin
immunohistochemically and determined its prognostic relevance.
MATERIALS AND METHODS
Patients
All oesophageal SCC patients, who were oesophagectomised at the
Benjamin Franklin University Clinics (Berlin) between 1982 and
1993, were analysed. Staging and 5-year follow-up was complete in
84 cases. Patients who died of postoperative complications within
30 days were excluded. The clinicopathological data are sum-
marised in Table 1.
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Immunohistochemical staining was performed using the standard
avidin–biotin–peroxidase kit (DAKO Hamburg, Germany).
Tumour sections (2–3mm), of adjacent normal squamous cell
epithelium and of any adjacent high-grade dysplasias, which were
found in 10 of the 84 cases, were evaluated. High-grade dysplasias
are now recommended by the WHO to be referred to as high-grade
intraepithelial neoplasia (Gabbert et al, 2000). Briefly, deparaffi-
nised sections were heated for 5min in 1mM EDTA buffer in a
pressure cooker to reactivate the antigen and were treated 30min
with 3% H2O2 in methanol to abolish endogenous peroxidase
activity. Sections were incubated with 0.25mg/ml anti survivin
antibody (NOVUS Biologicals Inc., Littleton, CO, USA) for 30min
at room temperature. Biotinylated anti-rabbit immunoglobulin
followed by avidin–biotin–peroxidase complex were applied.
Sections were developed with 20,40-diaminobenzidine and haema-
toxylin counterstaining. For ki-67 immunostaining, monoclonal
MIB-1-antibody (DAKO Hamburg, Germany) was used at a 1:1000
dilution and sections were stained by standard immunohisto-
chemical techniques (APAAP method), as described elsewhere
(Grabowski et al, 2001). Analysis of slides was performed in a
blinded fashion by the authors Ku ¨hnel, Grabowski and Heine,
without knowledge of clinicopathological data. Cases were scored
positive when more than 5% of the cells reacted with the anti
survivin antibody, as proposed by other authors (Kawasaki et al,
1998). The nuclear ki-67 labelling index was expressed as the
percentage of positively stained cells with respect to a hundred
cells in 10 high-power fields.
Statistical analysis
The w
2 test was used for comparison of data between groups.
Overall survivals were assessed by the Kaplan–Meier method. The
significance of differences in overall survival was calculated by the
Mantel–Cox log-rank test. Most biological and pathological
variables were used as dichotomised (categorial) variables: tissue
infiltration (T1–T2 vs T3–T4), lymph node involvement (N0 vs
N1–N2), grading (G1–G2 vs G3) and age (457 years vs o57
years). Univariate analysis was performed with the Cox regression
model. Differences were considered to be significant for Po0.05.
All statistical analyses were performed using SPSS software.
RESULTS
Survivin expression in normal squamous cell epithelium of
the oesophagus
Survivin expression was detected in all cases of normal squamous
cell epithelium of the oesophagus in the basal layer. At the cellular
level, survivin staining was predominantly cytoplasmic. Some
minimal nuclear immunoreactivity was also observed (Figure 1A).
The staining pattern and intensity of the normal squamous cell
epithelium were consistent in different specimens.
Survivin expression in dysplasia
Survivin was detected in dysplastic epithelial cells (Figure 1C).
In contrast to the distribution seen in normal squamous
epithelial cells, survivin staining in dysplasia was more intense
and uniformly distributed throughout the cytoplasm of all
dysplastic cells. Furthermore, the intensity of survivin staining
did not show a gradient from the lower layers toward the surface,
but was uniform throughout all levels of the lesion. In addition,
nuclear expression of survivin was found in some dysplastic cells
(Figure 1D).
Survivin expression in oesophageal SCC
Survivin staining was heterogeneous in oesophageal SCC. In 53
tumours (63%), a cytoplasmic expression of survivin was observed
(Figure 1E). A total of 67 tumours (80%) showed a positive nuclear
staining for survivin (Figure 1F). Both cytoplasmic and nuclear
staining was seen in 46 (55%) cases. Only 10 (12%) tumours did
not show any survivin expression at all. The staining within a
tumour was often heterogeneous. In areas adjacent to the normal
squamous cell epithelium, for example, cytoplasmic survivin
expression was present. In more infiltrative parts of the same
tumour, nuclear survivin expression occurred.
Evaluation of cell proliferation by ki-67
immunohistochemistry
All cases were evaluated for the immunohistochemical localisation
of ki-67, a marker of cell proliferation. The distribution of ki-67
staining in normal squamous cell epithelium, dysplasia and
carcinoma was similar to the distribution of survivin staining. At
the individual cellular level, as evaluated in paired serial sections,
there was some correlation between survivin and ki-67 staining.
However, many more cells were positive for the ki-67 antigen than
for survivin (Figures 1B and G).
Nuclear survivin expression and clinicopathological
parameters
Statistical correlation between nuclear survivin expression and sex,
age, tumour site or grading revealed no significant differences
between survivin
+ and survivin
  oesophageal SCC cases (w
2 test).
However, nuclear survivin expression was significantly increased
in primary SCC, which had metastasised into lymph nodes
(P¼0.001) or distant organs (P¼0.02). Moreover, tumours with
nuclear survivin expression presented with higher T-stages,
Table 1 Clinicopathological data of patients and tumours according to
nuclear survivin expression
Patients Nuclear survivin
No. % Positive % P-value
Total 84 67 79.7
Male 60 71.4 50 74.6 0.198
Female 24 28.6 17 25.4
Age (years)
Median 56.8 56.5 0.557
Range 37–84
T-stage 84 67
T1+T2 34 40.5 24 35.8 0.134
T3+T4 50 59.5 43 64.2
Lymph node metastasis 83 67
Node negative 32 38.6 20 29.9 0.001
Node positive 51 61.4 47 70.1
Grading 79 63
G1+G2 35 44.3 29 46 0.54
G3 44 55.7 34 54
UICC-stage 84 67
I 8 9.5 4 6 0.006
II 23 27.4 15 22.4
III 37 44 32 47.8
IV 16 19 16 23.9
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British Journal of Cancer (2003) 88(1), 115–119 & 2003 Cancer Research UKbut this trend did not reach statistical significance (P¼0.08,
Table 1).
Prognostic implications of nuclear survivin expression
Kaplan–Meier survival curves for patients with oesophageal
SCC, categorized according to nuclear survivin expression,
are shown in Figure 2. The mean survival of patients with nuclear
survivin expression (28 months, range 20–36) was significantly
less than that of patients with no nuclear survivin expression
(108 months, range 62–154; P¼0.0028, Mantel–Cox log-rank
test). Using univariate Cox regression analysis, nuclear survivin
expression (P¼0.003), depth of tumour invasion (P¼0.001),
lymph node metastasis (P¼0.003) and stage (Po0.001) were the
best predictors of survival of oesophageal SCC patients. In
contrast, cytoplasmic expression of survivin had no prognostic
relevance.
DISCUSSION
Survivin, a recently identified member of the family of apoptosis
inhibitors, is a bifunctional protein that suppresses apoptosis and
regulates cell division (Altieri et al, 1999). This protein has
attracted great interest as a potential drug target because its
expression appears to be tumour-specific (Velculescu et al, 1999).
While foetal tissues contain abundant survivin mRNA and protein,
most nonproliferating adult tissues do not. In contrast, the vast
Figure 1 Immunohistochemistry for detection of survivin in (A) normal oesophageal squamous cell epithelium, (C) high-grade dysplasia (predominant
cytoplasmic localisation), (D) high-grade dysplasia (predominant nuclear localisation), (E) oesophageal SCC (cytoplasmic localisation), (F) oesophageal SCC
(nuclear localisation). Immunohistochemistry for detection of ki-67 antigen in (B) normal oesophageal squamous cell epithelium (paired section to (A)) and
(G) oesophageal SCC (paired section to (F)). Scale bar¼100mm.
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British Journal of Cancer (2003) 88(1), 115–119 & 2003 Cancer Research UKmajority of cancers express survivin protein, suggesting that
reactivation of survivin gene expression occurs commonly in
cancers (Ambrosini et al, 1997). Correspondingly, previous reports
have shown that the presence of survivin is associated with poor
survival among patients with colorectal cancer (Kawasaki et al,
1998), non small-cell lung cancer (Monzo et al, 1999), breast
cancer (Tanaka et al, 2000) and neuroblastoma (Adida et al, 1998).
In our study on 84 patients with oesophageal SCC, we now show
that nuclear survivin protein is expressed in 80% of these tumours,
thereby confirming and extending earlier results on mRNA
expression of survivin in 51 oesophageal SCC patients (Kato et al,
2001). Furthermore, we could differentiate between cytoplasmic
and nuclear localisation of survivin protein expression and were
the first to show a translocation of survivin during carcinogenesis.
In normal squamous cell epithelium of the oesophagus, survivin
was mainly localised in the cytoplasm of the basal layers.
Cytoplasmic staining was also found in some high-grade dysplasia
and/or carcinoma, albeit throughout all levels of the neoplasia.
Additionally, nuclear survivin expression was observed in some
squamous epithelial cells, but much more in high-grade dysplasia
and in the corresponding tumours. The restriction of survivin
expression to the basal layers of the normal oesophageal squamous
cell epithelium suggests that survivin may be related to cell
proliferation. Accordingly, we performed serial microsection
immunostaining for survivin and ki-67, a marker of cell
proliferation, and observed some cellular congruence, but,
interestingly, many more cells stained for ki-67 than for survivin.
Similar findings were reported in normal colonic mucosa (Gianani
et al, 2001). One possible explanation is that ki-67 antigen is
expressed in every phase of the cell cycle (Endl and Gerdes, 2000),
whereas survivin is only present in the G2/M-phase of the cell cycle
(Li et al, 1998). In this context, the functional role of nuclear
survivin has been addressed in hepatocellular cancer (Ito et al,
2000). Here, the predominant function of survivin was not the
(cytoplasmic) caspase-3-dependent antiapoptotic effect, but the
cell cycle phase redistribution. The authors found that survivin
promoted cell proliferation by interacting with CDK4 and releasing
p21 from CDK4. In line with these findings, it was shown recently
(Rodriguez et al, 2002) that differences in the amino-acid sequence
of the carboxy-terminal domain of survivin determine the different
localisation of survivin in the cytoplasm and its splicing
variant survivin DEx3 in the nucleus. These novel findings suggest
that localisation of survivin may constitute an important
regulatory mechanism for its role in carcinogenesis and tumour
progression.
Accordingly, we show in our study that nuclear survivin
expression was nearly invariably associated with metastatic disease
to lymph nodes or distant organs. The advanced stage of disease in
this subgroup of patients may reflect the rapid growth and
aggressiveness of the tumour itself rather than a late diagnosis of a
slowly growing tumour. In contrast, cytoplasmic staining of
survivin had no prognostic relevance at all. Obviously, the former
described antiapoptotic function of survivin is not the predomi-
nant effect for tumour progressiveness in oesophageal SCC.
Similarly, no prognostic significance of cytoplasmic survivin was
found in gastric cancer (Okada et al, 2001). Altogether, our data on
84 patients with oesophageal SCC suggest that nuclear survivin
expression heralds a particularly poor prognosis. On the other
hand, lack of nuclear survivin expression identifies oesophageal
SCC patients with a favourable prognosis. Furthermore, we
provide evidence that localisation of survivin expression appears
to be crucial for its function in tumour cells and again stresses
dysregulation of cell cycle as a critical pathogenetic factor in
tumour progression.
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